ANN ARBOR, Mich., – July 22, 2024– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs“), announces the launch of its third and largest production cycle of the 2024 spider silk production season.

This cycle is being released in a set of scheduled batches, the first of which is already in production. This batch process is designed to address the upcoming peak of the rainy season while driving Kraig Labs toward its 2024 production volume goals.

This expanded production cycle was empowered by an additional production facility recently brought online. The Company is utilizing this newly constructed facility to support the continued expansion of silkworm rearing and silk production, avoiding the typical slowdowns due to rain.

Kraig Labs expects to bring additional facilities online over the next two months to increase its production footprint in support of its goal of delivering the first metric ton of spider silk to the global markets.

With each successive production cycle, the Company further validates its spider silk production model and that its specialized silkworms are ready for mass production. This now-fielded technology has broken through technical barriers, allowing for the large-scale commercial production of engineered spider silk using the cost-effective, time-tested, and established infrastructure for traditional silk.

“Our rearing operations continue to set new commercial spider silk production records. The first half of 2024 was a game-changer for the commercialization of spider silk, and we are expecting even greater things for the second half of the year,” said Company Founder and CEO, Kim Thompson. “This year has been an inflection point for Kraig Labs and for the limitless possibilities of spider silk commercialization.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – July 15, 2024– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today the completion of phase one construction for its production facility expansion. This project was completed on budget and on schedule. This facility is now ready to support the Company’s third production wave, which will begin this month. 

This additional production space will allow Kraig Labs to continue its production expansion during the rainy season when silk production is traditionally reduced. This new space provides the facilities for the Company to process, dry, and store fresh mulberry needed during the rainy season. With this new space, the Company can continue expanding its spider silk production.

Kraig Labs is also investing in a second, significantly larger project, constructing a new dedicated silkworm egg hatchery. This larger facility is expected to address the Company’s production needs for the next 12-18 months. Construction on this project is also underway. It is expected to be online before the end of the rainy season.

“These investments in production capacity expansion are a part of our systematic growth plan for commercial scale production of spider silk,” said the Company’s Founder and CEO, Kim Thompson. “These additional facilities will allow us to keep our foot on the accelerator, bringing cost-effective and eco-responsible spider silk to the global markets.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – July 8, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has signed a production agreement for the manufacturing of its recombinant spider silk technology. This production agreement builds upon the Company’s success with the rollout of its new spider silk production hybrids earlier this year.

Under the terms of this agreement, Kraig Labs will work with silk manufacturers to adapt their existing production facilities and networks to produce Kraig Labs proprietary spider silk.

The recently announced buildout of additional production facilities is a component of this agreement and the Company’s efforts to expand spider silk production.

“We are making big moves to bring commercial-scale spider silk manufacturing online. This agreement will allow us to expand our production foot print and capacity,” said Company Founder and CEO, Kim Thompson. “We will continue to take bold actions, take smart risks, and invest in endless possibilities that commercial scale spider silk has to offer.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – July 1, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has achieved full capacity at its current production location. Hitting this milestone was part of Kraig Labs’ expansion plans for the first half of 2024. The Company now reports that it is moving forward with its planned investment into additional production facilities.

Kraig Labs began planning for this factory expansion during the spring trials after witnessing the strong growth and robustness of its new spider silk hybrids.

This expansion is scheduled to take place in two waves. The first will address the near-term need for capacity during the upcoming rainy seasons, this will provide the needed secure space for production over the next several months. The second, larger project will address Kraig Labs’ longer-term need for hatchery space, which is expected to address production needs for the next 12-18 months.

Permitting for both of these projects has been approved and the Company is now moving forward with investment into both of these expansion projects. Construction for both investments has begun, with the first project expected to be completed within just a few weeks and the larger effort is scheduled to be completed by early fall.

“We have set ambitious goals for spider silk production in 2024, and we are committed to achieving and exceeding those targets,” said Company Found and CEO, Kim Thompson. “These investments into production capacity bring us one step closer to realizing our vision for cost-effective commercial scale production of spider silk.”

The Company expects to begin the third wave of recombinant spider silk production this month, focusing on scaling up the output of the parental lines for its production hybrids.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – June 25, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has expanded its production of spider silk with the creation of the next generation of BAM-1 hybrid. 

Kraig Labs recently announced the successful production of the first BAM-1 hybrid cocoons early this month. That production cycle ended with the significantly scaled-up output of hybrid eggs. These eggs were produced through careful selective breeding of the BAM-1 parental strains raised during this rearing cycle.

Based on the strong results of the last production batch, Kraig Labs elected to increase egg production this cycle. This represents the largest egg production in the Company’s history. These eggs are slated for rearing within the next 30 days.

The Company’s team is coordinating its rearing efforts and operational plans, for the next 60 days, to optimize its spider silk output, while factoring in the August weather cycle, which typically sees a reduction in traditional silk production due to heavy rains and suboptimal rearing conditions.

“The first half of 2024 has been, objectively, the most productive time in the Company’s history,” said Founder and CEO Kim Thompson. “We set some very aggressive goals for the BAM-1 hybrids and the expansion of spider silk production. We are hitting our marks with the business model and production schedule as the BAM-1 hybrids continue to demonstrate the robustness and performance.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – June 17, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has successfully completed cocoon production for the first commercial production run of its BAM-1 hybrids. The Company launched the BAM-1 hybrids 30 days ahead of schedule based on the overwhelming success of its spring production trials.

During the spring trials, Kraig labs raised the two separate BAM-1 parental lines with overwhelming success. At the end of those trials, the BAM-1 parent lines were cross-mated to create this first batch of commercial production BAM-1 hybrids.

This rearing of the BAM-1 hybrids represents a 10X increase in production volume when compared to the spring trials. This cycle has generated more than 325 pounds of recombinant spider silk cocoons that will be processed into finished recombinant spider silk. This is the largest batch of recombinant spider silk cocoons ever produced.

The BAM-1 hybrids are the latest development in the Company’s commercialization of recombinant spider silk. They were specifically designed to address the identified need for improved robustness to meet large-scale spider silk manufacturing needs.

Having proven its production efficiency, the Company is now preparing for further commercial expansion of the BAM-1 parental lines and significant scale-up in BAM-1 hybrids. Based on the results of production operations, the Company remains confident that it will achieve its metric-ton-level spider silk production goal.

“This first commercial production rearing of BAM-1 hybrids was a great success, representing the largest single batch we have ever produced to date. This production batch is just the beginning of what we believe will be a very exciting and rapid scale-up of spider silk production in 2024,” said Company Founder and CEO, Kim Thompson. “We will continue to move forward, taking smart risks, as we lead the commercialization of cost-effective and eco-responsible spider silk.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – June 11, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that production of its BAM-1 spider silk hybrid strain continues to set records for silkworm size, growth, and robustness. 

The Company announced in early June that it had accelerated its production schedule for its new BAM-1 hybrids based on the results of its spring production trials. The rearing of this first batch of production hybrids is now well underway. The Company is pleased to report that this is not only the largest single production batch in its history but also the strongest growing and most robust production batch the Company has produced. 

At more than ten times the size of the spring trials, this production batch is pushing the Company’s operational team to demonstrate the rapid scalability of its spider silk production technology. This production batch is validating the rearing protocols and systems put in place during the spring trials.

“Our mission has been, and will continue to be, the rapid commercialization of cost-effective and environmentally responsible spider silk production,” said Company CEO and Founder, Kim Thompson. “The development of the BAM-1 hybrids and the systems we have put in place with our operations team are rapidly transitioning that mission into reality.”

The Company expects to share reports on the results of the cocooning and processing of this batch of BAM-1 recombinant spider silk over the coming weeks. The Company continues to take bold moves as it aggressively moves forward, focusing on meeting its metric ton production targets.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – June 3, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that Kraig Labs is now in production with its BAM-1 recombinant spider silk hybrids. The Company originally planned this launch for July, but the resounding successes of the production trials positioned Kraig Labs to accelerate its 2024 production schedule.

This production cycle serves as a critical transition for the Company’s commercialization of sustainable and cost-effective spider silk production. This announcement marks the Company’s first transition of true production hybrids to the manufacturing environment. This rearing cycle also represents more than a 10X increase in production over the spring trials and is the largest single batch of spider silk production in the Company’s operating history.

The BAM-1 hybrids exhibited an excellent hatching yield and continue to show strong and uniform growth. The Company’s team has been closely monitoring their health and is proud to report that, just like the spring trials,  it has not observed any sign of disease or weakness within the colony.

The BAM-1 hybrids were created by integrating the Company’s recombinant spider silk technology, Dragon Silk^TM, into two robust commercial silkworm strains. These two silkworm strains created the parental lines that, when combined, produce the BAM-1 hybrids. The BAM-1 hybrids result in the largest cocoons and most robust silkworms Kraig Labs has producedThis, in turn, results in higher silk yield and improved production efficiency, while maintaining fiber material performance, as the Company scales up its spider silk production operations.

“This successful launch of the BAM-1 hybrids is the result of more than a year of focused development by our team. The spring production trials demonstrated that we have brought together the right team, the right technology, and the right facilities to make 2024 a breakout year for the commercialization of spider silk,” said Founder and CEO of Kraig Labs, Kim Thompson. “This cycle puts us securely on the path to reaching our first production milestone of a metric ton of spider silk.”

Over the coming weeks, the Company will provide additional updates on this production cycle and its plans for continued production growth and end-market developments.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – May 28, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”)  announces an update on the commercialization of its BAM-1 recombinant spider silk production hybrids.

First made public in February of 2024, as part of the Company’s now successfully concluded spring production trails, the BAM-1 hybrid is the latest development in recombinant spider silk production technology.

Kraig Labs’ BAM-1 production platform has proven to be the most robust and resilient production system for commercial-scale production of recombinant spider silk. What sets the BAM-1 system apart from previous developments is the strong and robust commercial genetic backbone that these strains were developed into.

The BAM-1 hybrid system represents a major advancement in the production capacity for the Company’s spider silk commercialization efforts. This new production platform integrates the Company’s spider silk technologies into production-ready silkworm strains. 

BAM-1 is a silk production system developed by Kraig Labs to serve as an integration platform for its recombinant spider silk technologies. The BAM-1 hybrids produce Dragon Silk^TM, one of the Company’s major recombinant spider silk technology breakthroughs. Kraig Labs developed Dragon Silk to blend spider silk’s incredible physical and chemical properties with commercially scalable technology leveraging mundane silk production infrastructure.

The Company’s merger of the BAM-1 hybrid manufacturing technologies with the cutting-edge bio-engineering of Dragon Silk has created what Kraig Labs believes to be the most advanced and scalable spider silk production system in existence.

“The BAM-1 hybrids have been a huge success, and they are unlocking the powerful potential of our spider silk technologies,” said Kim Thompson, Founder and CEO of Kraig Labs. “The BAM-1 hybrids have proven to be a scalable and reliable platform for Dragon Silk manufacturing. As we bring the next generation of pure spider silk technologies to market, the BAM-1 production system will serve to rapidly accelerate their transition to commercialization.”

Due to the success of its spring production trials, the Company remains ahead of schedule for its 2024 production season. It expects to provide further details of that production expansion in the coming weeks.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – May 20, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has completed its analysis of its spring spider silk production trials. Kraig Labs is rapidly integrating lessons learned from the production trials to establish a strong foundation for production expansion in 2024.

The Company identified key input parameters in five specific aspects of its production operations that contributed to the exceptional results in the spring trials. Through the identification and close monitoring of these inputs, Kraig Labs expects that it will be able to sustain its projected  growth trajectory, targeting metric ton levels of spider silk production in 2024.

These process enhancements range from major advancements in our silkworm genetics introduced in Q1, to minor modifications in feeding cycles, feedstock selection, and facility layout. When combined, these process improvements resulted in the largest, strongest, and most robust silkworms and recombinant spider silk cocoons that Kraig Labs has ever produced.

While the details of these operational advancements will remain the Company’s trade secrets, these enhancements broadly fall into five unique categories: nutrition, climate, genetic, staffing, and rearing conditions. Kraig Labs made significant advancements in each of these areas during the spring trials under the guidance of celebrated sericulture expert, Dr. Nirmal Kumar. 

“The amazing successes of the spring production trials demonstrate that we have unlocked the key to metric ton level spider silk production,” said Founder and CEO, Kim Thompson. “Our team is ready. Our silkworm genetics are ready. Now is the time to build out the production capacity and scale our operations to meet the demand for spider silk.”

With these operational improvements in place, the Company has elected to accelerate its launch of larger-scale operations and accelerate its production schedule. The next generation of BAM-1 spider silk hybrids are now prepared for launch nearly a full month ahead of schedule. Kraig Labs will continue to keep its shareholders updated as the BAM-1 hybrid production expansion continues and the Company brings additional production capacity online.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com